Physician profile
Eric Mcdade
NPI 1073649265
$63,179.06
in general payments reported to CMS, 2019-2025
11 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,668 · 2020: $3,150 · 2021: $5,090 · 2022: $9,935 · 2023: $12K · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Travel and Lodging: $2,926 · Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,787.25 |
| Travel and Lodging | $2,926.09 |
| Food and Beverage | $622.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $12,947.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $12,896.50 | 2023-2025 | |
| Eli Lilly and Company | $11,889.83 | 2020-2024 | Kisunla |
| Janssen Global Services, LLC | $7,286.23 | 2025 | |
| Sanofi US Services INC. | $7,244.00 | 2022-2025 | |
| Eisai INC. | $3,840.00 | 2019 | |
| Sage Therapeutics, LLC | $3,717.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $1,800.00 | 2022 | |
| F. Hoffmann-La Roche Ag | $1,120.00 | 2023 | |
| Grifols Shared Services North America, INC. | $438.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mcdade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.